Publications by authors named "Henry Grabowski"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

797

Total Likes

45

Extended Reach

69,158

Social Features

18
O
Oncology Drugs: The Authors Reply.
Henry Grabowski, Joseph A DiMasi, Genia Long

Health Aff (Millwood)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations.
David Proudman, Urvi Desai, Dumingu Aparna Gomes, Maks Khomenko, Silas Martin, Henry Grabowski

J Med Econ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postapproval Innovation For Oncology Drugs And The Inflation Reduction Act.
Henry Grabowski, Joseph A DiMasi, Genia Long

Health Aff (Millwood)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act.
Henry Grabowski, Genia Long

J Med Econ· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuing trends in U.S. brand-name and generic drug competition.
Henry Grabowski, Genia Long, Richard Mortimer, Mehmet Bilginsoy

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products.
Mark W Skinner, P Ann Hedlund Hoppe, Henry G Grabowski, Richard Manning, Raffi Tachdjian

Transfusion· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated trends in US brand-name and generic drug competition.
Henry Grabowski, Genia Long, Richard Mortimer, Ani Boyo

J Med Econ· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost of drug development.
Joseph A DiMasi, Henry G Grabowski, Ronald W Hansen

N Engl J Med· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The roles of patents and research and development incentives in biopharmaceutical innovation.
Henry G Grabowski, Joseph A DiMasi, Genia Long

Health Aff (Millwood)· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Henry G Grabowski, Rahul Guha, Maria Salgado

Health Aff (Millwood)· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does generic entry always increase consumer welfare?
Henry Grabowski, Tracy Lewis, Rahul Guha, Zoya Ivanova, Maria Salgado

Food Drug Law J· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent trends in brand-name and generic drug competition.
Henry Grabowski, Genia Long, Richard Mortimer

J Med Econ· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilar competition: lessons from Europe.
Henry Grabowski, Rahul Guha, Maria Salgado

Nat Rev Drug Discov· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
Henry G Grabowski, Margaret Kyle, Richard Mortimer, Genia Long, Noam Kirson

Health Aff (Millwood)· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of the biosimilar pathway: economic and policy issues.
Henry Grabowski, Genia Long, Richard Mortimer

Seton Hall Law Rev· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data exclusivity for biologics.
Henry Grabowski, Genia Long, Richard Mortimer

Nat Rev Drug Discov· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA review vouchers.
Jeffrey Moe, Henry Grabowski, David Ridley

N Engl J Med· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic returns of pediatric clinical trials of antihypertensive drugs.
Carissa M Baker-Smith, Daniel K Benjamin, Henry G Grabowski, Elizabeth D Reid, Barry Mangum

Am Heart J· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
Henry G Grabowski, Jeffrey L Moe

Cancer Prev Res (Phila)· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-on biologics: data exclusivity and the balance between innovation and competition.
Henry Grabowski

Nat Rev Drug Discov· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misleading congress about drug development: Reply.
Joseph A Dimasi, Ronald W Hansen, Henry G Grabowski

J Health Polit Policy Law· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The market for follow-on biologics: how will it evolve?
Henry Grabowski, Iain Cockburn, Genia Long

Health Aff (Millwood)· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic return of clinical trials performed under the pediatric exclusivity program.
Jennifer S Li, Eric L Eisenstein, Henry G Grabowski, Elizabeth D Reid, Barry Mangum

JAMA· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economics of new oncology drug development.
Joseph A DiMasi, Henry G Grabowski

J Clin Oncol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis